Humanized Liver Mice Model Market is estimated to be US$ 133.72 billion by 2030 with a CAGR of 5.30% during the forecast period

Humanized Liver Mice Model Market accounted for US$ 78.64 million in 2020 and is estimated to be US$ 133.72 million by 2030 and is anticipated to register a CAGR of 5.30%. A lot of studies are underway to create novel humanized liver mouse models. Initially, liver mice models were created by implanting human liver cells or hepatic cancer cells into basic immune-deficient mice. The results, however, were inconsistent and unreliable. As a result, immune-deficient mice were developed, which spontaneously destroy the mice liver, allowing human liver cells to proliferate and replace it, resulting in stable humanized liver mice models. For example, a number of research projects are looking into using PPARalfa and AFC8-based mice models to develop humanized liver mice models.

The report **"Global Humanized Liver Mice Model Market, By Model (uPA-SCID, FRG KO Mice, TK-NOG Mice and Other Models) By Application (Pharmacokinetics Studies, In-vivo Liver Toxicity Testing, Drug Metabolism Studies and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030''**

Key Highlights:

- In Dec 2021, The commercial introduction of CN Bio's new PhysioMimixTM OOC Multi-Organ MPS, a leading developer of single and multi-organ microphysiological systems (MPS), also known as organ-on-a-chip (OOC), was announced. The next-generation platform combines CN Bio's in vitro 3D liver model, whose phenotype and functions are similar to those seen in humans, with a variety of other organs to better replicate the multi-organ and systemic effects seen in humans.

Analyst View:

An increase in the number of FDA approvals for liver-based disease therapies has resulted in an increase in the number of research and development activities that require these models, such as the rising incidence of liver cirrhosis, technological advancement, and the development of new humanised liver mice. The growing number of drug approvals reflects the extent of research and toxicity studies, which includes pre-clinical investigations utilising illness animal models, such as humanised liver mice.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4829

Key Market Insights from the report:

Global Humanized Liver Mice Model Market accounted for US$ 78.64 million in 2020 and is estimated to be US$ 133.72 million by 2030 and is anticipated to register a CAGR of 5.30%. The Global Humanized Liver Mice Model Market is segmented based on model, application and region.

- Based on Model, Global Humanized Liver Mice Model Market is segmented into uPA-SCID, FRG KO Mice, TK-NOG Mice and Other Models.

- Based on Application, Global Humanized Liver Mice Model Market is segmented into Pharmacokinetics Studies, In-vivo Liver Toxicity Testing, Drug Metabolism Studies and Others.
- By Region, the Global Humanized Liver Mice Model Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.